|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Dyba T, Randi G, Bettio M, Gavin A, Visser O and Bray F: Cancer
incidence and mortality patterns in Europe: Estimates for 40
countries and 25 major cancers in 2018. Eur J Cancer. 103:356–387.
2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lheureux S, Gourley C, Vergote I and Oza
AM: Epithelial ovarian cancer. Lancet. 393:1240–1253.
2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Colombo N, Sessa C, du Bois A, Ledermann
J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I,
Vergote I, et al: ESMO-ESGO consensus conference recommendations on
ovarian cancer: Pathology and molecular biology, early and advanced
stages, borderline tumours and recurrent disease. Ann Oncol.
30:672–705. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chase DM, Chaplin DJ and Monk BJ: The
development and use of vascular targeted therapy in ovarian cancer.
Gynecol Oncol. 145:393–406. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Liu FW, Cripe J and Tewari KS:
Anti-angiogenesis therapy in gynecologic malignancies. Oncology
(Williston Park). 29:350–360. 2015.PubMed/NCBI
|
|
6
|
Perren TJ, Swart AM, Pfisterer J,
Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P,
Cervantes A, Kurzeder C, et al: A phase 3 trial of bevacizumab in
ovarian cancer. N Engl J Med. 365:2484–2496. 2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Burger RA, Brady MF, Bookman MA, Fleming
GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE,
et al: Incorporation of bevacizumab in the primary treatment of
ovarian cancer. N Engl J Med. 365:2473–2483. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Aghajanian C, Blank SV, Goff BA, Judson
PL, Teneriello MG, Husain A, Sovak MA, Yi J and Nycum LR: OCEANS: A
randomized, double-blind, placebo-controlled phase III trial of
chemotherapy with or without bevacizumab in patients with
platinum-sensitive recurrent epithelial ovarian, primary
peritoneal, or fallopian tube cancer. J Clin Oncol. 30:2039–2045.
2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Aghajanian C, Goff B, Nycum LR, Wang YV,
Husain A and Blank SV: Final overall survival and safety analysis
of OCEANS, a phase 3 trial of chemotherapy with or without
bevacizumab in patients with platinum-sensitive recurrent ovarian
cancer. Gynecol Oncol. 139:10–16. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Coleman RL, Brady MF, Herzog TJ, Sabbatini
P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley
DM, et al: Bevacizumab and paclitaxel-carboplatin chemotherapy and
secondary cytoreduction in recurrent, platinum-sensitive ovarian
cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): A
multicentre, open-label, randomised, phase 3 trial. Lancet Oncol.
18:779–791. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Pujade-Lauraine E, Hilpert F, Weber B,
Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P,
Bamias A, et al: Bevacizumab combined with chemotherapy for
platinum-resistant recurrent ovarian cancer: The AURELIA open-label
randomized phase III trial. J Clin Oncol. 32:1302–1308.
2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Cancer Genome Atlas Research Network.
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ledermann J, Harter P, Gourley C,
Friedlander M, Vergote I, Rustin G, Scott C, Meier W,
Shapira-Frommer R, Safra T, et al: Olaparib maintenance therapy in
platinum-sensitive relapsed ovarian cancer. N Engl J Med.
366:1382–1392. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Moore K, Colombo N, Scambia G, Kim BG,
Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke
GS, et al: Maintenance olaparib in patients with newly diagnosed
advanced ovarian cancer. N Engl J Med. 379:2495–2505.
2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pujade-Lauraine E, Ledermann JA, Selle F,
Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A,
Pignata S, et al: Olaparib tablets as maintenance therapy in
patients with platinum-sensitive, relapsed ovarian cancer and a
BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised,
placebo-controlled, phase 3 trial. Lancet Oncol. 18:1274–1284.
2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mirza MR, Monk BJ, Herrstedt J, Oza AM,
Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I,
et al: Niraparib maintenance therapy in platinum-sensitive,
recurrent ovarian cancer. N Engl J Med. 375:2154–2164.
2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
González-Martín A, Pothuri B, Vergote I,
DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D,
Hoskins P, Freyer G, et al: Niraparib in patients with newly
diagnosed advanced ovarian cancer. N Engl J Med. 381:2391–2402.
2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Swisher EM, Lin KK, Oza AM, Scott CL,
Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM,
et al: Rucaparib in relapsed, platinum-sensitive high-grade ovarian
carcinoma (ARIEL2 Part 1): An International, multicentre,
open-label, phase 2 trial. Lancet Oncol. 18:75–87. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Coleman RL, Oza AM, Lorusso D, Aghajanian
C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G,
et al: Rucaparib maintenance treatment for recurrent ovarian
carcinoma after response to platinum therapy (ARIEL3): A
randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 390:1949–1961. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tsibulak I, Zeimet AG and Marth C: Hopes
and failures in front-line ovarian cancer therapy. Crit Rev Oncol
Hematol. 143:14–19. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Joo WD, Visintin I and Mor G: Targeted
cancer therapy-Are the days of systemic chemotherapy numbered?
Maturitas. 76:308–314. 2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Dumont S, Jan Z, Heremans R, Van Gorp T,
Vergote I and Timmerman D: Organoids of epithelial ovarian cancer
as an emerging preclinical in vitro tool: A review. J Ovarian Res.
12(105)2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Maru Y and Hippo Y: Current status of
patient-derived ovarian cancer models. Cells. 8(505)2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Clevers H: Modeling development and
disease with organoids. Cell. 165:1586–1597. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sato T, Vries RG, Snippert HJ, van de
Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters
PJ and Clevers H: Single Lgr5 stem cells build crypt-villus
structures in vitro without a mesenchymal niche. Nature.
459:262–265. 2009.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Maenhoudt N, Defraye C, Boretto M, Jan Z,
Heremans R, Boeckx B, Hermans F, Arijs I, Cox B, Van Nieuwenhuysen
E, et al: Developing organoids from ovarian cancer as experimental
and preclinical models. Stem Cell Reports. 14:717–729.
2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
de Witte CJ, Espejo Valle-Inclan J, Hami
N, Lõhmussaar K, Kopper O, Vreuls CPH, Jonges GN, van Diest P,
Nguyen L, Clevers H, et al: Patient-derived ovarian cancer
organoids mimic clinical response and exhibit heterogeneous inter-
and intrapatient drug responses. Cell Rep.
31(107762)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Vlachogiannis G, Hedayat S, Vatsiou A,
Jamin Y, Fernández-Mateos J, Khan K, Lampis A, Eason K, Huntingford
I, Burke R, et al: Patient-derived organoids model treatment
response of metastatic gastrointestinal cancers. Science.
359:920–926. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lõhmussaar K, Boretto M and Clevers H:
Human-derived model systems in gynecological cancer research.
Trends Cancer. 6:1031–1043. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Sato T, Stange DE, Ferrante M, Vries RG,
Van Es JH, Van den Brink S, Van Houdt WJ, Pronk A, Van Gorp J,
Siersema PD and Clevers H: Long-term expansion of epithelial
organoids from human colon, adenoma, adenocarcinoma, and Barrett's
epithelium. Gastroenterology. 141:1762–1772. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Boj SF, Hwang CI, Baker LA, Chio II, Engle
DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, et al:
Organoid models of human and mouse ductal pancreatic cancer. Cell.
160:324–338. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yan HHN, Siu HC, Law S, Ho SL, Yue SSK,
Tsui WY, Chan D, Chan AS, Ma S, Lam KO, et al: A comprehensive
human gastric cancer organoid biobank captures tumor subtype
heterogeneity and enables therapeutic screening. Cell Stem Cell.
23:882–897.e11. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Gao D, Vela I, Sboner A, Iaquinta PJ,
Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora
VK, et al: Organoid cultures derived from patients with advanced
prostate cancer. Cell. 159:176–187. 2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Sachs N, de Ligt J, Kopper O, Gogola E,
Bounova G, Weeber F, Balgobind AV, Wind K, Gracanin A, Begthel H,
et al: A living biobank of breast cancer organoids captures disease
heterogeneity. Cell. 172:373–386.e10. 2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Li X, Francies HE, Secrier M, Perner J,
Miremadi A, Galeano-Dalmau N, Barendt WJ, Letchford L, Leyden GM,
Goffin EK, et al: Organoid cultures recapitulate esophageal
adenocarcinoma heterogeneity providing a model for clonality
studies and precision therapeutics. Nat Commun.
9(2983)2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lee SH, Hu W, Matulay JT, Silva MV,
Owczarek TB, Kim K, Chua CW, Barlow LJ, Kandoth C, Williams AB, et
al: Tumor evolution and drug response in patient-derived organoid
models of bladder cancer. Cell. 173:515–528.e17. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Girda E, Huang EC, Leiserowitz GS and
Smith LH: The use of endometrial cancer patient-derived organoid
culture for drug sensitivity testing is feasible. Int J Gynecol
Cancer. 27:1701–1707. 2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ooft SN, Weeber F, Dijkstra KK, McLean CM,
Kaing S, van Werkhoven E, Schipper L, Hoes L, Vis DJ, van de Haar
J, et al: Patient-derived organoids can predict response to
chemotherapy in metastatic colorectal cancer patients. Sci Transl
Med. 11(eaay2574)2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Drost J and Clevers H: Organoids in cancer
research. Nat Rev Cancer. 18:407–418. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Weeber F, van de Wetering M, Hoogstraat M,
Dijkstra KK, Krijgsman O, Kuilman T, Gadellaa-van Hooijdonk CG, van
der Velden DL, Peeper DS, Cuppen EP, et al: Preserved genetic
diversity in organoids cultured from biopsies of human colorectal
cancer metastases. Proc Natl Acad Sci USA. 112:13308–13311.
2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
DeHaan RK, Sarvestani SK and Huang EH:
Organoid models of colorectal pathology: Do they hold the key to
personalized medicine? A systematic review. Dis Colon Rectum.
63:1559–1569. 2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Yao Y, Xu X, Yang L, Zhu J, Wan J, Shen L,
Xia F, Fu G, Deng Y, Pan M, et al: Patient-derived organoids
predict chemoradiation responses of locally advanced rectal cancer.
Cell Stem Cell. 26:17–26.e6. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
van de Wetering M, Francies HE, Francis
JM, Bounova G, Iorio F, Pronk A, van Houdt W, van Gorp J,
Taylor-Weiner A, Kester L, et al: Prospective derivation of a
living organoid biobank of colorectal cancer patients. Cell.
161:933–945. 2015.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Nanki Y, Chiyoda T, Hirasawa A, Ookubo A,
Itoh M, Ueno M, Akahane T, Kameyama K, Yamagami W, Kataoka F and
Aoki D: Patient-derived ovarian cancer organoids capture the
genomic profiles of primary tumours applicable for drug sensitivity
and resistance testing. Sci Rep. 10(12581)2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Kessler M, Hoffmann K, Brinkmann V, Thieck
O, Jackisch S, Toelle B, Berger H, Mollenkopf HJ, Mangler M,
Sehouli J, et al: The Notch and Wnt pathways regulate stemness and
differentiation in human fallopian tube organoids. Nat Commun.
6(8989)2015.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Kopper O, de Witte CJ, Lõhmussaar K,
Valle-Inclan JE, Hami N, Kester L, Balgobind AV, Korving J, Proost
N, Begthel H, et al: An organoid platform for ovarian cancer
captures intra- and interpatient heterogeneity. Nat Med.
25:838–849. 2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Phan N, Hong JJ, Tofig B, Mapua M,
Elashoff D, Moatamed NA, Huang J, Memarzadeh S, Damoiseaux R and
Soragni A: A simple high-throughput approach identifies actionable
drug sensitivities in patient-derived tumor organoids. Commun Biol.
2(78)2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Maru Y, Tanaka N, Itami M and Hippo Y:
Efficient use of patient-derived organoids as a preclinical model
for gynecologic tumors. Gynecol Oncol. 154:189–198. 2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Jabs J, Zickgraf FM, Park J, Wagner S,
Jiang X, Jechow K, Kleinheinz K, Toprak UH, Schneider MA, Meister
M, et al: Screening drug effects in patient-derived cancer cells
links organoid responses to genome alterations. Mol Syst Biol.
13(955)2017.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Hill SJ, Decker B, Roberts EA, Horowitz
NS, Muto MG, Worley MJ Jr, Feltmate CM, Nucci MR, Swisher EM,
Nguyen H, et al: Prediction of DNA repair inhibitor response in
short-term patient-derived ovarian cancer organoids. Cancer Discov.
8:1404–1421. 2018.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Hoffmann K, Berger H, Kulbe H,
Thillainadarasan S, Mollenkopf HJ, Zemojtel T, Taube E,
Darb-Esfahani S, Mangler M, Sehouli J, et al: Stable expansion of
high-grade serous ovarian cancer organoids requires a low-Wnt
environment. EMBO J. 39(e104013)2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Sun H, Wang H and Wang X, Aoki Y and Wang
X, Yang Y, Cheng X, Wang Z and Wang X: Aurora-A/SOX8/FOXK1
signaling axis promotes chemoresistance via suppression of cell
senescence and induction of glucose metabolism in ovarian cancer
organoids and cells. Theranostics. 10:6928–6945. 2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Nero C, Vizzielli G, Lorusso D, Cesari E,
Daniele G, Loverro M, Scambia G and Sette C: Patient-derived
organoids and high grade serous ovarian cancer: From disease
modeling to personalized medicine. J Exp Clin Cancer Res.
40(116)2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Wensink GE, Elias SG, Mullenders J,
Koopman M, Boj SF, Kranenburg OW and Roodhart JML: Patient-derived
organoids as a predictive biomarker for treatment response in
cancer patients. NPJ Precis Oncol. 5(30)2021.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Fleming M, Ravula S, Tatishchev SF and
Wang HL: Colorectal carcinoma: Pathologic aspects. J Gastrointest
Oncol. 3:153–173. 2012.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Haeberle L and Esposito I: Pathology of
pancreatic cancer. Transl Gastroenterol Hepatol.
4(50)2019.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Tiriac H, Belleau P, Engle DD, Plenker D,
Deschênes A, Somerville TDD, Froeling FEM, Burkhart RA, Denroche
RE, Jang GH, et al: Organoid profiling identifies common responders
to chemotherapy in pancreatic cancer. Cancer Discov. 8:1112–1129.
2018.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Weeber F, Ooft SN, Dijkstra KK and Voest
EE: Tumor organoids as a Pre-clinical cancer model for drug
discovery. Cell Chem Biol. 24:1092–1100. 2017.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Aboulkheyr Es H, Montazeri L, Aref AR,
Vosough M and Baharvand H: Personalized cancer medicine: An
organoid approach. Trends Biotechnol. 36:358–371. 2018.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Klement GL, Arkun K, Valik D, Roffidal T,
Hashemi A, Klement C, Carmassi P, Rietman E, Slaby O, Mazanek P, et
al: Future paradigms for precision oncology. Oncotarget.
7:46813–46831. 2016.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Matchar DB: Chapter 1: Introduction to the
methods guide for medical test reviews. J Gen Intern Med. 27 (Suppl
1):S4–S10. 2012.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Behjati S, Huch M, van Boxtel R, Karthaus
W, Wedge DC, Tamuri AU, Martincorena I, Petljak M, Alexandrov LB,
Gundem G, et al: Genome sequencing of normal cells reveals
developmental lineages and mutational processes. Nature.
513:422–425. 2014.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Drost J, van Boxtel R, Blokzijl F,
Mizutani T, Sasaki N, Sasselli V, de Ligt J, Behjati S, Grolleman
JE, van Wezel T, et al: Use of CRISPR-modified human stem cell
organoids to study the origin of mutational signatures in cancer.
Science. 358:234–238. 2017.PubMed/NCBI View Article : Google Scholar
|
